|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/26/19 Immunomedics Inc 8-K:8,9 12/26/19 12:214K Globenewswire Inc./FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 21K 2: EX-99.1 Press Release HTML 15K 12: R1 Cover HTML 45K 7: XML IDEA XML File -- Filing Summary XML 12K 11: XML XBRL Instance -- f8k_122419_htm XML 14K 9: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.DEF XBRL Definitions -- gnw-20190101_def XML 71K 5: EX-101.LAB XBRL Labels -- gnw-20190101_lab XML 99K 6: EX-101.PRE XBRL Presentations -- gnw-20190101_pre XML 68K 3: EX-101.SCH XBRL Schema -- gnw-20190101 XSD 13K 8: JSON XBRL Instance as JSON Data -- MetaLinks 26± 34K 10: ZIP XBRL Zipped Folder -- 0001171843-19-008312-xbrl Zip 15K
| Form 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM i 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i December 26, 2019
_______________________________
i IMMUNOMEDICS, INC.
(Exact name of registrant as specified in its charter)
_______________________________
| i Delaware | i 000-12104 | i 61-1009366 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
i 300 The American Road
i Morris Plains, i New Jersey i 07950
(Address of Principal Executive Offices) (Zip Code)
( i 973) i 605-8200
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company,indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| i Common Stock, $0.01 par value | i IMMU | i Nasdaq Stock Market LLC |
On December 26, 2019, Immunomedics, Inc. (the “Company”), a Delaware corporation, issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company’s resubmission of its Biologics License Application seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
(d) The following exhibit is being filed herewith:
| Exhibit No. | Exhibit | |
| 99.1 | Press Release of Immunomedics, Inc. dated December 26, 2019 | |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNOMEDICS, INC. | ||
| Date: December 26, 2019 | By: | /s/ Usama Malik |
| Name: Usama Malik | ||
| Title: Chief Financial Officer | ||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 12/26/19 | None on these Dates | ||
| List all Filings | ||||